Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

INJESTA SOFT CAPSULE 200MG [SIN17386P]

Active ingredients: INJESTA SOFT CAPSULE 200MG

View product's general information
Last updated 24 April 2026

Product Info

INJESTA SOFT CAPSULE 200MG

[SIN17386P]

Product information

Active Ingredient and Strength

PROGESTERONE MICRONIZED - 200 MG

Dosage Form

CAPSULE, LIQUID FILLED

Manufacturer and Country

JSC FARMAK - UKRAINE

Registration Number

SIN17386P

Licence Holder

GOLDPLUS UNIVERSAL PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

G03DA04

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATION
Injesta is indicated for:
Disorders related to progesterone deficit in particular menstrual irregularities due to ovulation disorders or anovulation, premenstrual disorders, breast pain or by benign breast disorders (mastopathies), bleeding due to fibroma, therapy of menopause (adjunctive use with estrogen in post-menopausal women for prevention of endometrial hyperplasia), menace of preterm delivery and can be used up to 36 week of pregnancy, threatened miscarriage or prevention of habitual miscarriage due to luteal phase deficiency up to the 12th week of pregnancy, treatment of subfertility or primary or secondary infertility related to progesterone insufficiency in particular in In Vitro Fertilization cycles and/or oocyte donation.
For all other progesterone indications, the vaginal route represents an alternative to the oral route, in case of adverse events due to progesterone (somnolence, dizziness).

Dosing

RECOMMENDED DOSAGE
On the average for progesterone deficiencies, the daily dose is 200mg to 300 mg divided into one or two intakes, 100mg in the morning or 200mg at bedtime. In some cases, notably to help pregnancy, the doctor may increase the dose to 600mg per day, divided into three intakes.
For threatened abortion, 200–400mg per day to be taken in the acute phase from the start to 12th week of pregnancy.
For menace for preterm delivery, 400mg every 6 to 8 hours depending on the clinical response during the acute phase then a dosage of 3 x 200mg/day as maintenance treatment until the 36th week of pregnancy.
In hormone replacement therapy in post menopausal women receiving estrogen therapy, treatment can be prescribed continuously or sequentially for at least 12 days per month.

Contraindications

CONTRAINDICATIONS
Injesta should not be used in individuals with any of the following conditions:
* known allergy or hypersensitivity to progesterone or to any of the excipients
* severe hepatic dysfunction

* undiagnosed vaginal bleeding

* known missed abortion or ectopic pregnancy

* mammary or genital tract carcinoma

* thromboembolic or thrombophlebitis disorders

* cerebral haemorrhage

* porphyria.